Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

C I Falkson

Showing results (21-30 of 42) with videos related to

Pageof 5
Sort By:
European Journal of Cancer (Oxford, England : 1990)|January 1, 1991
Effect of chemotherapy with or without buserelin on serum hormone levels in premenopausal women with breast cancerC I Falkson, H C Falkson, G Falkson
Annals of Oncology : Official Journal of the European Society for Medical Oncology|April 1, 1991
Long term follow-up of patients with advanced prostatic cancer treated with nasal buserelinC I Falkson, G Falkson, H C Falkson
Investigational New Drugs|November 1, 1990
High versus low dose granisetron, a selective 5HT3 antagonist, for the prevention of chemotherapy-induced nausea and vomitingH C Falkson, C I Falkson, G Falkson
Drugs & Aging|March 1, 1993
Postmenopausal breast cancer. Drug therapy in the 1990sC I Falkson, G Falkson, H C Falkson
Cancer|October 1, 1990
Survival of premenopausal women with metastatic breast cancer. Long-term follow-up of Eastern Cooperative Group and Cancer and Leukemia Group B studiesG Falkson, R S Gelman, L Leone, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 1, 1991
Factors predicting for response, time to treatment failure, and survival in women with metastatic breast cancer treated with DAVTH: a prospective Eastern Cooperative Oncology Group studyG Falkson, R Gelman, C I Falkson, et al.
Oncology|January 1, 1992
Mitomycin C + high-dose medroxyprogesterone versus cyclophosphamide+doxorubicin plus fluorouracil as first-line treatment for metastatic breast cancerC I Falkson, G Falkson, C B Falkson, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 1, 1994
Reinduction with the same cytostatic treatment in patients with metastatic breast cancer: an Eastern Cooperative Oncology Group studyG Falkson, R Gelman, J Glick, et al.
American Journal of Clinical Oncology|February 1, 1993
A randomized trial of mitomycin-C (M) versus mitomycin-C plus high-dose medroxyprogesterone acetate (MMPA) in the treatment of patients with advanced breast cancerC I Falkson, G Falkson, C B Falkson, et al.
Oncology|January 1, 1988
Cyclophosphamide, mitoxantrone, vincristine and prednisone in the treatment of non-Hodgkin's lymphomaD A Vorobiof, A P Terblanche, C I Falkson, et al.
Pageof 5

Showing results (21-30 of 42) with videos related to

Sort By:
Pageof 5
European Journal of Cancer (Oxford, England : 1990)|January 1, 1991
Effect of chemotherapy with or without buserelin on serum hormone levels in premenopausal women with breast cancerC I Falkson, H C Falkson, G Falkson
Annals of Oncology : Official Journal of the European Society for Medical Oncology|April 1, 1991
Long term follow-up of patients with advanced prostatic cancer treated with nasal buserelinC I Falkson, G Falkson, H C Falkson
Investigational New Drugs|November 1, 1990
High versus low dose granisetron, a selective 5HT3 antagonist, for the prevention of chemotherapy-induced nausea and vomitingH C Falkson, C I Falkson, G Falkson
Drugs & Aging|March 1, 1993
Postmenopausal breast cancer. Drug therapy in the 1990sC I Falkson, G Falkson, H C Falkson
Cancer|October 1, 1990
Survival of premenopausal women with metastatic breast cancer. Long-term follow-up of Eastern Cooperative Group and Cancer and Leukemia Group B studiesG Falkson, R S Gelman, L Leone, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 1, 1991
Factors predicting for response, time to treatment failure, and survival in women with metastatic breast cancer treated with DAVTH: a prospective Eastern Cooperative Oncology Group studyG Falkson, R Gelman, C I Falkson, et al.
Oncology|January 1, 1992
Mitomycin C + high-dose medroxyprogesterone versus cyclophosphamide+doxorubicin plus fluorouracil as first-line treatment for metastatic breast cancerC I Falkson, G Falkson, C B Falkson, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 1, 1994
Reinduction with the same cytostatic treatment in patients with metastatic breast cancer: an Eastern Cooperative Oncology Group studyG Falkson, R Gelman, J Glick, et al.
American Journal of Clinical Oncology|February 1, 1993
A randomized trial of mitomycin-C (M) versus mitomycin-C plus high-dose medroxyprogesterone acetate (MMPA) in the treatment of patients with advanced breast cancerC I Falkson, G Falkson, C B Falkson, et al.
Oncology|January 1, 1988
Cyclophosphamide, mitoxantrone, vincristine and prednisone in the treatment of non-Hodgkin's lymphomaD A Vorobiof, A P Terblanche, C I Falkson, et al.
Pageof 5